Delivery Order SPE2DR25D1053-SPE2DR26FT735
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 22, 2025, for NovoLog 100 unit/mL vials (10mL) with a ceiling value of $3,212.64. This firm fixed-price delivery order is non-competitive and represents a single transaction under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The place of performance is AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 11, 2025, for the supply of NovoLog 100 Unit/mL insulin vials (10mL) with a contract ceiling value of $1,476.24. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, with an ultimate completion date of July 14, 2025. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of NovoLog 100 Unit/mL vials (10 mL) with a ceiling value of $2,515.17. This is a firm fixed-price delivery order with no set-aside designation, issued competitively under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999.999 billion through December 2026. The place of performance is AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of NovoLog 100 Unit/mL vials (10 mL) with a ceiling value of $6,072.14. This is a firm fixed-price delivery order issued without set-aside provisions, indicating competitive award to a qualified vendor. The contract is performed from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of July 25, 2025. This delivery...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $1,296.60 for NovoLog 100 Unit/mL vials (10 mL) on August 12, 2025, with completion targeted for August 13, 2025. The contract employs firm fixed pricing with no set-aside designation, indicating competitive procurement. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this delivery order at its corporate office location in the...
- The Defense Logistics Agency awarded a delivery order valued at $1,994.41 to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL vials (10mL) with a firm fixed price and an ultimate completion date of November 3, 2025. The award, made on October 31, 2025, is a non-set-aside competitive contract for pharmaceutical supply to support federal medical procurement needs. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for the Defense Logistics...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of NovoLog 100 Unit/mL vials (10 mL) with a ceiling value of $4,628.92. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded to support federal medical procurement needs. The contract is scheduled for completion by September 29, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a $3,362.46 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of NovoLog 100 Unit/mL vials (10mL), with an ultimate completion date of September 19, 2025. This contract was competitively awarded without set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves...
- The Defense Logistics Agency awarded a $2,540.18 delivery order to AmerisourceBergen Drug Corp on October 27, 2025, for the supply of NovoLog 100 Unit/mL vials (10 mL). The contract, which employs firm fixed-price terms, is scheduled for completion by October 28, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This is a non-set-aside competitive award, reflecting AmerisourceBergen's demonstrated capability to meet federal pharmaceutical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 23, 2025, for the supply of NovoLog 100 Unit/mL vials (10 mL) with a ceiling value of $1,380.94. This non-set-aside contract represents a firm fixed price delivery order with an ultimate completion date of October 24, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical...
- SPE2DR25D1053Indefinite Delivery Contract
- SPE2DR25D1053-SPE2DR26FT735Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 7, 2025, for the supply of NovoLog 100 Unit/mL vials (10 mL) with a ceiling value of $3,562.05. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation and an ultimate completion date of November 10, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems. This delivery order is executed under AmerisourceBergen Drug Corp's Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion comprehensive global pharmaceutical support vehicle running through December 2026. The IDC enables the contractor to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, including specialty medications, brand-name and generic drugs, and related medical commodities. The current order for insulin products supports federal healthcare operations administered by the Defense Health Agency and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.6k | 11/7/25 |